NCT05301972No Longer Available不适用
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor
Bristol-Myers Squibb0 个研究点开始时间: 2022年3月31日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
研究概览
简要总结
This is an expanded access designed to provide access to Bromodomain and Extra-Terminal (BET) Inhibitor for eligible participants.
研究设计
- 研究类型
- Expanded Access
入排标准
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Available
不适用
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalSarcomaColorectal Cancer (CRC)Non-Small Cell Lung Cancer (NSCLC)Hepatocellular Carcinoma (HCC)Ovarian CancerPancreatic CancerMelanomaProstate CancerNCT06751524Agenus Inc.
No Longer Available
不适用
Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant PatientsSolid Organ Transplant RejectionOrgan Rejection TransplantsOrgan RejectionNCT05215288Direct Biologics, LLC
No Longer Available
不适用
Expanded Access to Bimatoprost (Durysta)Open-angle GlaucomaNCT05338606AbbVie
No Longer Available
不适用
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)NCT05086094Biohaven Pharmaceuticals, Inc.
Available
不适用
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)Spinocerebellar AtaxiasSCANCT06034886Biohaven Pharmaceuticals, Inc.